Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti–B7-H3 × PD-L1 Antibody–Drug Conjugate
DB-1419 demonstrated potent antitumor activity against multiple tumors, with favorable pharmacokinetic and safety profiles. These preclinical data potentially position DB-1419 as a promising treatment approach, currently in the ongoing phase I/IIa study in advanced tumors (NCT06554795).
Authors
- Chenggang Li (ORCID: https://orcid.org/0000-0001-8981-4585)
- Jun Yao (ORCID: https://orcid.org/0000-0003-0781-5694)
- Haiqing Hua (ORCID: https://orcid.org/0000-0002-6714-0708)
- Junjie Yang
- Yu Zhang
- Yang Qiu
- Zhongyuan Zhu
Institutions
- Cell Biologics (United States) (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-06-11
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0634
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 4.18